Actively Recruiting
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Led by Dana-Farber Cancer Institute · Updated on 2026-05-07
30000
Participants Needed
1
Research Sites
782 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
CONDITIONS
Official Title
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 30 years or older
- Self-identified African American race and/or first-degree relative of a patient with a plasma cell disorder such as MGUS, SMM, multiple myeloma, or Waldenström's Macroglobulinemia, or another blood cancer
- Individuals over 18 years old with two or more family members diagnosed with a blood cancer
You will not qualify if you...
- Persons diagnosed with any cancer requiring active treatment
- Persons already diagnosed with plasma cell disorders such as MGUS, SMM, multiple myeloma, or Waldenström's Macroglobulinemia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
I
Irene Ghobrial, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here